These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27216036)

  • 41. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern.
    Currie CJ; Johnson JA
    Diabetes Obes Metab; 2012 Jan; 14(1):1-4. PubMed ID: 21736688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The need for better insulin therapy.
    Grunberger G
    Diabetes Obes Metab; 2013 Mar; 15 Suppl 1():1-5. PubMed ID: 23448196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diabetes, injection technic and patient education].
    Mosnier-Pudar H
    Soins; 2010 May; (745):17. PubMed ID: 20509482
    [No Abstract]   [Full Text] [Related]  

  • 45. HypoAware: development and pilot study of a brief and partly web-based psychoeducational group intervention for adults with Type 1 and insulin-treated Type 2 diabetes and problematic hypoglycaemia.
    Rondags SM; de Wit M; Snoek FJ
    Diabet Med; 2016 Feb; 33(2):184-91. PubMed ID: 26234919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of insulin diluent leakage postinjection using two different needle lengths and injection volumes in obese patients with type 1 or type 2 diabetes mellitus.
    Ignaut DA; Fu H
    J Diabetes Sci Technol; 2012 Mar; 6(2):389-93. PubMed ID: 22538152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Management of diabetes in general practice--current requirements. 2: Oral antidiabetics and insulin therapy].
    Mehnert H
    Fortschr Med; 1994 Apr; 112(12):163-6. PubMed ID: 8200602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An interprofessional qualitative study of barriers and potential solutions for the safe use of insulin in the hospital setting.
    Rousseau MP; Beauchesne MF; Naud AS; Leblond J; Cossette B; Lanthier L; Grondin F; Bernier F
    Can J Diabetes; 2014 Apr; 38(2):85-9. PubMed ID: 24690502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors.
    Vardar B; Kizilci S
    Diabetes Res Clin Pract; 2007 Aug; 77(2):231-6. PubMed ID: 17303282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Do patients with diabetes use the insulin pen properly?
    Tosun B; Cinar FI; Topcu Z; Masatoglu B; Ozen N; Bagcivan G; Kilic O; Demirci C; Altunbas A; Sonmez A
    Afr Health Sci; 2019 Mar; 19(1):1628-1637. PubMed ID: 31148992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of lipohypertrophy.
    Kalra S; Kumar A; Gupta Y
    J Pak Med Assoc; 2016 Jul; 66(7):910-1. PubMed ID: 27427150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The economic effect of hypoglycemia in a health plan.
    Heaton A; Martin S; Brelje T
    Manag Care Interface; 2003 Jul; 16(7):23-7. PubMed ID: 12908214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Hypoglycemia in diabetic children].
    Tupola S; Rajantie J
    Duodecim; 2000; 116(2):125-31. PubMed ID: 11764469
    [No Abstract]   [Full Text] [Related]  

  • 54. Individualizing care with injectable glucose-lowering agents.
    Miller EM
    J Fam Pract; 2013 Dec; 62(12 Suppl CME):S12-9. PubMed ID: 24340344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Poor glycaemic control caused by insulin induced lipohypertrophy.
    Chowdhury TA; Escudier V
    BMJ; 2003 Aug; 327(7411):383-4. PubMed ID: 12919996
    [No Abstract]   [Full Text] [Related]  

  • 56. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insulin-mediated lipohypertrophy: an uncommon cause of diabetic ketoacidosis.
    Barola A; Tiwari P; Bhansali A
    BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28801327
    [No Abstract]   [Full Text] [Related]  

  • 58. UK lipohypertrophy interventional study.
    Smith M; Clapham L; Strauss K
    Diabetes Res Clin Pract; 2017 Apr; 126():248-253. PubMed ID: 28288434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The management of insulin administration: systematic review and recommendations].
    Romanin M; Chiandetti R; Comisso I; Palese A
    Assist Inferm Ric; 2011; 30(3):144-54. PubMed ID: 22076627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insulin-induced lipodystrophy and interest of insulin injection ports.
    Ben Abdelkrim A; Fathallah N; Omri M; Hasni Y; Khaldi S; Kacem M; Chaieb M; Ben Salem C; Maaroufi A; Ach K
    Therapie; 2019 Dec; 74(6):680-682. PubMed ID: 31088690
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.